Relationship between BrainAge Polygenetic Risk Score and plasma biomarkers in the A4/LEARN studies
Year: 2025
Type: preprint
Abstract: Background and Objectives To examine the association between genetic predisposition to accelerated brain aging—measured with polygenic risk scores (PRS) derived from BrainAge models—and plasma biomarkers of Alzheimer’s disease (AD), with attention to age and sex-specific effects. Methods We analyzed 1994 cognitively unimpaired participants from the A4/LEARN studies (71.5±4.8 years; 41% male). We computed the genetic risk of accelerated grey matter loss associated with age using GWAS data from previous studies. Baseline plasma biomarkers included pTau 217 (N=980; Eli Lilly immunoassay), and GFAP and NfL (N=1636; Roche Elecsys immunoassay). General linear models tested associations between each PRS and each biomarker, including PRS-by-age interaction terms. Analyses were additionally stratified by sex. Results BrainAge PRS moderated the association between age and pTau 217 levels (β=0.08±0.03, p=0.0086), such that higher PRS for BrainAge was associated with increased pTau 217 at older ages. Results were robust to covariates. This association was significant in females but not in males. No significant associations were found with GFAP or NfL. Discussion Genetic risk for accelerated grey matter loss with aging is associated with elevated pTau 217 levels in cognitively unimpaired older females. These findings suggest a sex- and age-specific genetic link between brain aging and early AD pathology.
Source: medRxiv
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Alzheimer's Association, Eli Lilly and Company, Foundation for Neurologic Diseases, GHR Foundation, Ikerbasque, Basque Foundation for Science, Ministerio de Ciencia e Innovación, Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona, National Institutes of Health, National Institute on Aging
Awards: G2290189609, G2772962269, The inactive X: discovering sex genes that influence female vulnerability to Alzheimer's disease, Menopause, Hormone Therapy and Clinicopathology: An In-Vivo Perspective, Neuroimage-Genetic Integration to Investigate Risk and Resilience in AD, G4944594896, G5132640529, Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study, G6004110409, G7685134749, Alzheimer's Disease Cooperative Study, G8347645112, Building predictive algorithms to identify resilience and resistance to Alzheimer's disease, Menopause, hormone therapy and Alzheimer's disease clinicopathology: An in vivo perspective
OpenAlex ID: W4412168608
